The PI3K/AKT/mTOR pathway is frequently deregulated in breast cancer by different mechanisms, leading to increased PI3K activity and/or loss of PI3K inhibitory functions as well as mutation in tumor suppressor genes like INPP4B and PTEN phosphatases. This evidence concerns the gene MTOR and breast carcinoma.